See: Puoti et al. Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation? Antiviral Therapy 2004; 9:627–630.
References
1.
PuotiM., BabudieriS., RezzaG., VialeP., AntoniniM.G., MaidaI., RossiS., ZaniniB., PutzoluV., FenuL., BaigueraC., SassuS., CarosiG., & MuraM.S.Use of pegylated interferons is associated with an increased incidence of infections during combination treatment of chronic hepatitis C: a side effect of pegylation?Antiviral Therapy2004; 9: 627–630.
2.
BaronS., CoppenhaverD.H., & DianzaniF.Introduction to the interferon system. In Principles and Medical applications.1992; pp 1–5. Edited by BaronS.. Galveston, TX: UTMN.
3.
LavermanP., DamsE.T., StormG., HafmansT.G., CroesH.J., OyenW.J., CorstensF.H., & BoermanO.C.Microscopic localization of PEG-liposomes in a rat model of focal infection.Journal of Controlled Release2001; 75: 347–355.
VentoS., Di PerriG., CrucianiM., garofanoT., ConciaE., & BassettiD.Rapid decline of CD4+ cells after interferon treatment in HIV-1 infection.Lancet1993; 341: 958–959.
